Butyrate affects differentiation, maturation and function of human monocyte-derived dendritic cells and macrophages

Clinical and Experimental Immunology

Volumn 130, Issue 2, 2002, Pages 245-255

  Millard, A L ^a   Mertes, P M ^b   Ittelet, D ^c   Villard, F ^d   Jeannesson, P ^a   Bernard, J ^c  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c INSTITUT JEAN GODINOT   (France)

^d ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

Butyrate; Dendritic cells; Immunosuppression; Macrophages; Monocytes

Indexed keywords

BUTYRIC ACID; CD14 ANTIGEN; CD86 ANTIGEN; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; MEMBRANE ANTIGEN;

ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; HUMAN; HUMAN CELL; IMMATURITY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MACROPHAGE; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL;

ANTIGEN PRESENTATION; BUTYRATES; CALCITRIOL; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; DRUG SYNERGISM; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE CULTURE TEST, MIXED; MACROPHAGES; MONOCYTES; PHAGOCYTOSIS; STEM CELLS; T-LYMPHOCYTES;

EID: 0036404925     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0009-9104.2002.01977.x     Document Type: Article

References (57)

1. Suthanthiran M, Rubin AL, Novogrodsky A, Stenzel KH. Immunosuppressive properties of polar organic compounds that induce cellular differentiation in Friend erythroleukemia cells. Transplantation 1982; 33:534-40.
2. Bohmig GA, Krieger PM, Saemann MD et al. Stable prodrugs of n-butyric acid: Suppression of T cell alloresponses in vitro and prolongation of heart allograft survival in a fully allogeneic rat strain combination. Transpl Immunol 1999; 7:221-7.
3. Gilbert KM, Wahid R, Fecher NP, Freeman JP, Fifer EK. Potential clinical use of butyric acid derivatives to induce antigen-specific T cell inactivation. J Pharmacol Exp Ther 2000; 294:1146-53.
4. Velazquez OC, Lederer HM, Rombeau JL. Butyrate and the colonocyte. Production, absorption, metabolism, and therapeutic implications. Adv Exp Med Biol 1997; 427:123-34.
5. Scheppach W, Bartram HP, Richter F. Role of short-chain fatty acids in the prevention of colorectal cancer. Eur J Cancer 1995; 31A:1077-80.
6. Harig JM, Soergel KH, Komorowski RA, Wood CM. Treatment of diversion colitis with short-chain-fatty acid irrigation. N Engl J Med 1989; 320:23-8.
7. Chapman MA, Grahn MF, Boyle MA, Hutton M, Rogers J, Williams NS. Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. Gut 1994; 35:73-6.
8. Ahmad MS, Krishnan S, Ramakrishna BS, Mathan M, Pulimood AB, Murthy SN. Butyrate and glucose metabolism by colonocytes in experimental colitis in mice. Gut 2000; 46:493-9.
9. Stenzel KH, Schwartz R, Rubin AL, Novogrodsky A. Chemical inducers of differentiation in Friend leukaemia cells inhibit lymphocyte mitogenesis. Nature 1980; 285:106-8.
10. Novogrodsky A, Rubin AL, Stenzel KH. A new class of inhibitors of lymphocyte mitogenesis: Agents that induce erythroid differentiation in Friend leukemia cells. J Immunol 1980; 124:1892-7.
11. Bohmig GA, Csmarits B, Cerwenka A, Alaei P, Kovarik J, Zlabinger GJ. Induction of alloantigen-specific hyporesponsiveness in vitro by the short-chain fatty acid N-butyrate. Transplantation 1995; 59:1500-3.
12. Kyner D, Zabos P, Christman J, Acs G. Effect of sodium butyrate on lymphocyte activation. J Exp Med 1976; 144:1674-8.
13. Gilbert KM, Weigle WO. Th1 cell anergy and blockade in G1a phase of the cell cycle. J Immunol 1993; 151:1245-54.
14. Bohmig GA, Krieger PM, Saemann MD, Wenhardt C, Pohanka E, Zlabinger GJ. n-Butyrate downregulates the stimulatory function of peripheral blood-derived antigen-presenting cells: A potential mechanism for modulating T-cell responses by short-chain fatty acids. Immunology 1997; 92:234-43.
15. Ingulli E, Mondino A, Khoruts A, Jenkins MK. In vivo detection of dendritic cell antigen presentation to CD4 (+) T cells. J Exp Med 1997; 185:2133-41.
16. Rappolee DA, Mark D, Banda MJ, Werb Z. Wound macrophages express TGF-alpha and other growth factors in vivo: Analysis by mRNA phenotyping. Science 1988; 241:708-12.
17. Andreesen R, Scheibenbogen C, Brugger W et al. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: A new approach to cancer immunotherapy. Cancer Res 1990; 50:7450-6.
18. Lopez M, Martinache C, Canepa S, Chokri M, Scotto F, Bartholeyns J. Autologous lymphocytes prevent the death of monocytes in culture and promote, as do GM-CSF, IL-3 and M-CSF, their differentiation into macrophages. J Immunol Meth 1993; 159:29-38.
19. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179:1109-18.
20. Romani N, Gruner S, Brang D et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180:83-93.
21. Rieser C, Bock G, Klocker H, Bartsch G, Thurnher M. Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: Synergistic activation of interleukin 12 production. J Exp Med 1997; 186:1603-8.
22. Kalinski P, Hilkens CM, Snijders A, Snijdewint FG, Kapsenberg ML. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol 1997; 159:28-35.
23. Eymard JC, Lopez M, Cattan A, Bouche O, Adjizian JC, Bernard J. Phase I/II trial of autologous activated macrophages in advanced colorectal cancer. Eur J Cancer 1996; 32A:1905-11.
24. Bernard J, Ittelet D, Christoph A et al. Adherent-free generation of functional dendritic cells from purified blood monocytes in view of potential clinical use. Hematol Cell Ther 1998; 40:17-26.
25. Hilkens CM, Kalinski P, de Boer M, Kapsenberg ML. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 1997; 90:1920-6.
26. Dunn PA, Tyrer HW. Quantitation of neutrophil phagocytosis, using fluorescent latex beads. Correlation of microscopy and flow cytometry. J Laboratory Clin Med 1981; 98:374-81.
27. Crow MK, Kunkel HG. Human dendritic cells: Major stimulators of the autologous and allogeneic mixed leucocyte reactions. Clin Exp Immunol 1982; 49:338-46.
28. + dendritic cells. Proc Natl Acad Sci USA 1996; 93:2588-92.
29. Kreutz M, Andreesen R. Induction of human monocyte to macrophage maturation in vitro by 1,25-dihydroxyvitamin D3. Blood 1990; 76:2457-61.
30. Canning MO, Grotenhuis K, de Wit H, Ruwhof C, Drexhage HA. 1-alpha,25-Dihydroxyvitamin D3 (1,25 (OH) (2) D (3) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol 2001; 145:351-7.
31. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52.
32. Bohmig GA, Kovarik J, Holter W, Pohanka E, Zlabinger GJ. Specific down-regulation of proliferative T cell alloresponsiveness by interference with CD2/LFA-3 and LFA-1/ICAM-1 in vitro. J Immunol 1994; 152:3720-8.
33. Piemonti L, Monti P, Sironi M et al. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 2000; 164:4443-51.
34. Yoshida M, Tanaka Y, Eguchi T, Ikekawa N, Saijo N. Effect of hexafluoro-1,25-dihydroxyvitamin D3 and sodium butyrate combination on differentiation and proliferation of HL-60 leukemia cells. Anticancer Res 1992; 12:1947-52.
35. 3 on neoplastic and osteoblastic phenotype in clonal rat osteosarcoma cells. Biochem Biophys Res Commun 1984; 121:796-801.
36. Tanaka Y, Bush KK, Klauck TM, Higgins PJ. Enhancement of butyrate-induced differentiation of HT-29 human colon carcinoma cells by 1,25-dihydroxyvitamin D3. Biochem Pharmacol 1989; 38:3859-65.
37. Gaschott T, Werz O, Steinmeyer A, Steinhilber D, Stein J. Butyrate-induced differentiation of Caco-2 cells is mediated by vitamin D receptor. Biochem Biophys Res Commun 2001; 288:690-6.
38. Singh H, Sen R, Baltimore D, Sharp PA. A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes. Nature 1986; 319:154-8.
39. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12:141-79.
40. Ammon C, Mondal K, Andreesen R, Krause SW. Differential expression of the transcription factor NF-kappaB during human mononuclear phagocyte differentiation to macrophages and dendritic cells. Biochem Biophys Res Commun 2000; 268:99-105.
41. Inan MS, Rasoulpour RJ, Yin L, Hubbard AK, Rosenberg DW, Giardina C. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. Gastroenterology 2000; 118:724-34.
42. Saemann MD, Bohmig GA, Osterreicher CH et al. Anti-inflammatory effects of sodium butyrate on human monocytes: Potent inhibition of IL-12 and up-regulation of IL-10 production. Faseb J 2000; 14:2380-2.
43. Scheppach W, Sommer H, Kirchner T et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 1992; 103:51-6.
44. Butzner JD, Parmar R, Bell CJ, Dalal V. Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat. Gut 1996; 38:568-73.
45. Kanauchi O, Andoh A, Iwanaga T et al. Germinated barley foodstuffs attenuate colonic mucosal damage and mucosal nuclear factor kappa B activity in a spontaneous colitis model. J Gastroenterol Hepatol 1999; 14:1173-9.
46. Andoh A, Bamba T, Sasaki M. Physiological and anti-inflammatory roles of dietary fiber and butyrate in intestinal functions. JPEN J Parenter Enteral Nutr 1999; 23:S70-3.
47. Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 1999; 94:427-33.
48. Daniel P, Brazier M, Cerutti I et al. Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts. Clin Chim Acta 1989; 181:255-63.
49. Pouillart P, Cerutti I, Ronco G, Villa P, Chany C. Butyric monosaccharide ester-induced cell differentiation and anti-tumor activity in mice. Importance of their prolonged biological effect for clinical applications in cancer therapy. Int J Cancer 1991; 49:89-95.
50. Planchon P, Raux H, Magnien V et al. New stable butyrate derivatives alter proliferation and differentiation in human mammary cells. Int J Cancer 1991; 48:443-9.
51. Pouillart P, Cerutti I, Ronco G, Villa P, Chany C. Enhancement by stable butyrate derivatives of antitumor and antiviral actions of interferon. Int J Cancer 1992; 51:596-601.
52. Chen ZX, Breitman TR. Tributyrin: A prodrug of butyric acid for potential clinical application in differentiation therapy. Cancer Res 1994; 54:3494-9.
53. Planchon P, Magnien V, Starzec A, Prevost G. Selection of a highly tumorigenic breast cancer cell line sensitive to estradiol to evidence in vivo the tumor-inhibitory effect of butyrate derivative Monobut-3. Life Sci 1994; 55:951-9.
54. Jenkins MK, Chen CA, Jung G, Mueller DL, Schwartz RH. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol 1990; 144:16-22.
55. Gilbert KM, Hoang KD, Weigle WO. Th1 and Th2 clones differ in their response to a tolerogenic signal. J Immunol 1990; 144:2063-71.
56. Liu Y, Jones B, Aruffo A, Sullivan KM, Linsley PS, Janeway CA Jr. Heat-stable antigen is a costimulatory molecule for CD4 T cell growth. J Exp Med 1992; 175:437-45.
57. Tan P, Anasetti C, Hansen JA et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993; 177:165-73.